Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 M...
Q3 2026
May 13, 2026
Q2 2026
Feb 17, 2026
Q1 2026
Nov 14, 2025
FY 2025
Sep 23, 2025
Q4 2025